Biomarin Pharmaceutical Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
© -
All right. Great. So welcome, everyone, to Credit Suisse's 30th Annual Healthcare Conference. I'm Tiago Fauth. I'm a biotech analyst here at Credit Suisse. We're joined today by BioMarin. I have JJ on the line, Jeff and Brian. So I appreciate you guys participating.
Feel free to e-mail me any questions that you might have, and I'll try to work those into the fireside chat. The e-mail is [email protected]. And as usual, we can probably get started with some broad remarks, a recap of the year, key focus areas, and we'll start to go into a little bit more detail after that. But J.J., I don't know if you want to take it away.
Okay. Thank you. Thank you, Tiago. We appreciate the opportunity to join you today. So with just a few weeks left in 2021, we look forward to 2022 with great excitement as we consider the growth opportunity ahead, with potential U.S
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |